Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
RESEARCH TOOLSreports
Holding MIRM?
Track your performance easily
MIRM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$23.14 - $45.23
Previous Close$40.72
Volume438.22K
Average Volume (3M)379.23K
Market Cap
$1.93B
Enterprise Value$1.97B
Total Cash (Recent Filing)$278.37M
Total Debt (Recent Filing)$316.56M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Nov 12, 2024EPS Estimate
-$0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.34
Shares Outstanding47,707,204
10 Day Avg. Volume285,674
30 Day Avg. Volume379,227
Standard Deviation0.35
R-Squared0.03
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)8.56
Price to Sales (P/S)7.35
Price to Cash Flow (P/CF)-127.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.44
Enterprise Value/Gross Profit14.12
Enterprise Value/Ebitda-47.66
Forecast
1Y Price Target
$59.88Price Target Upside45.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Mirum Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Drug Development And Market PotentialVolixibat is seen as a potentially complementary therapy for patients on other treatments for PBC, offering further pruritus relief.
Earnings And Financial PerformanceMirum Pharmaceuticals remains on track to hit its 2024 revenue guidance of $310-$320M with several recent wins across its pipeline.
Regulatory MilestonesThe FDA has granted Breakthrough Therapy Designation to volixibat as a potential treatment for cholestatic pruritus in patients with primary biliary cholangitis.
Bears Say
Product SafetyThe new label includes a warning to monitor for propylene glycol toxicity in younger patients.
Regulatory ApprovalsFailure to secure additional regulatory approvals for LIVMARLI.
Sales GrowthSales growth of LIVMARLI for ALGS and PFIC significantly below expectations.
---
Ownership Overview
9.71% Insiders
25.94% Mutual Funds
4.18% Other Institutional Investors
47.34% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MIRM FAQ
What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?
Mirum Pharmaceuticals Inc lowest stock price was $23.14 and its highest was $45.23 in the past 12 months.
What is Mirum Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?
Mirum Pharmaceuticals Inc’s upcoming earnings report date is Nov 12, 2024 which is in 2 days.
How were Mirum Pharmaceuticals Inc’s earnings last quarter?
Mirum Pharmaceuticals Inc released its earnings results on Aug 07, 2024. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.472 by -$0.048.
Is Mirum Pharmaceuticals Inc overvalued?
According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued.
Does Mirum Pharmaceuticals Inc pay dividends?
Mirum Pharmaceuticals Inc does not currently pay dividends.
What is Mirum Pharmaceuticals Inc’s EPS estimate?
Mirum Pharmaceuticals Inc’s EPS estimate is -$0.45.
How many shares outstanding does Mirum Pharmaceuticals Inc have?
Mirum Pharmaceuticals Inc has 47,707,203 shares outstanding.
What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?
Mirum Pharmaceuticals Inc reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.472. Following the earnings report the stock price went up 2.336%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?
Among the largest hedge funds holding Mirum Pharmaceuticals Inc’s share is Woodline Partners LP. It holds Mirum Pharmaceuticals Inc’s shares valued at 7M.
---
Mirum Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.88 (45.73% Upside)
$59.88 (45.73% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 71%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 96.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $13.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.73%
12-Months-Change
Fundamentals
Return on Equity
-69.35%
Trailing 12-Months
Asset Growth
48.96%
Trailing 12-Months
Company Description
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.
---
MIRM Earnings Call
Q2 2024
0:00 / 0:00
---
MIRM Stock 12 Month Forecast
Average Price Target
$59.88
▲(45.73% Upside)
Technical Analysis
Apellis Pharmaceuticals
―
Immunovant
―
Ultragenyx Pharmaceutical
―
SAGE Therapeutics
―
Best Analysts Covering MIRM
1 Year
1 Year Success Rate
30/32 ratings generated profit
1 Year Average Return
+34.37%
reiterated a buy rating last month
Copying Ed Arce's trades and holding each position for 1 Year would result in 93.75% of your transactions generating a profit, with an average return of +34.37% per trade.
---